KIT and neoplasm: However, at a dosage of 20 mg/kg b.i.d., 75 showed excellent regression of tumor volume (75%), and the data are encouraging when compared with regorafenib (39%) at 100 mg/kg q.d. In a Ba/F3 KIT-exon 11 del/V654A mouse allograft tumor model, 75 displayed strong regression (85%) at a dosage of 20 mg/kg b.i.d., but sunitinib showed similar regression (87%) at a dosage of 80 mg/kg q.d.